Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

18 Apr 2019

Abstract excerpt

Abstract Oncogenic MYC activation promotes proliferation in Burkitt lymphoma, but also induces cell-cycle arrest and apoptosis mediated by p53, a tumor suppressor that is mutated in 40% of Burkitt lymphoma cases. To identify molecular dependencies in Burkitt lymphoma, we performed RNAi-based, loss-of-function screening in eight Burkitt lymphoma cell lines and integrated non-Burkitt lymphoma RNAi screens and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31000522
DOI: 10.1158/0008-5472.can-18-3438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt LymphomaPMID 31000522Read ↗

MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphomaSemantic proximity Read ↗

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome LevelSemantic proximity Read ↗

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing.Semantic proximity Read ↗

Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targetsSemantic proximity Read ↗

The genetic landscape of mutations in Burkitt lymphoma.Semantic proximity Read ↗

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.Semantic proximity Read ↗

EBV and 1q Gains Affect Gene and miRNA Expression in Burkitt LymphomaSemantic proximity Read ↗

The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphomaSemantic proximity Read ↗

Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.Semantic proximity Read ↗

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read ↗

Identifying the determinants of response to MDM2 inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.